Bristol Myers Squibb (BMY) Depreciation & Amortization (CF) (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $594.0 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 41.3% year-over-year to $594.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.6 billion (down 55.53% YoY) and the FY2025 annual result came in at $4.0 billion, down 58.22% from the prior year.
• Depreciation & Amortization (CF) eased to $594.0 million in Q1 2026 per BMY's latest filing, from $977.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.6 billion in Q2 2024 and bottomed at $594.0 million in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $2.4 billion (2023), against an average of $2.0 billion.
• The widest annual swing landed in 2024, when Depreciation & Amortization (CF) gained 6.74%; it then tumbled 61.06% in 2025.
• Tracing BMY's Depreciation & Amortization (CF) over 5 years: stood at $2.5 billion in 2022, then slipped by 2.26% to $2.5 billion in 2023, then decreased by 23.7% to $1.9 billion in 2024, then sank by 48.03% to $977.0 million in 2025, then tumbled by 39.2% to $594.0 million in 2026.
• Per Business Quant, the three latest BMY Depreciation & Amortization (CF) figures stand at $594.0 million (Q1 2026), $977.0 million (Q4 2025), and $1.0 billion (Q3 2025).

Peer Comparison